Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raluca Alexandru
Institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra
Observed institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada,
Universidad de Navarra
ORCID:
0009-0002-1903-5636
Observed ORCID:
0009-0002-1903-5636
OpenAlex ID:
A5069183126
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
2024
·
Iñaki Eguren-Santamaria
, Eva Fernández de Piérola
, et al.
·
Journal for ImmunoTherapy of Cancer
·
21
PDF
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
2023
·
Javier Glez-Vaz
, Arantza Azpilikueta
, et al.
·
Science Advances
·
12
PDF
A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
2025
·
Maria Alsina
, Guillermo Villacampa
, et al.
·
Clinical Cancer Research
·
8
PDF
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
2026
·
Alvaro Lopez-Janeiro
, José González-Gomariz
, et al.
·
Journal of Clinical Investigation
·
5
PDF
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
·
Clinical Cancer Research
·
5
The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas
2025
·
Alvaro Lopez-Janeiro
, Emilia Brizzi
, et al.
·
Cells
·
3
PDF
T cell cross-priming by PD-L1+ type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1×4-1BB bispecific antibody
2026
·
Carlos Luri-Rey
, Inmaculada Rodríguez
, et al.
·
Immunity
·
1
PDF
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment
2026
·
Elixabet Bolaños
, Lorena Cañas-Zabala
, et al.
·
The Journal of Experimental Medicine
·
1
PDF
CD70 overexpression at diagnosis predicts relapse and supports dual CD19-CD70 CAR T-cell therapy in follicular lymphoma
2026
·
Ferran Araujo-Ayala
, Maria Ros
, et al.
·
Blood
·
1
Comprehensive Spatial Methods (CSM): a Toolbox for Spatially Analyzing Tissues in Histopathology
2025
·
Alvaro Lopez-Janeiro
, Eduardo Miraval-Wong
, et al.
·
Laboratory Investigation
·
1
1115 Cross-priming by type-1 conventional dendritic cells is critically involved in the efficacy of radiotherapy against cancer
2026
·
Maria Rodriguez-Ruiz
, Leticia Fernandez-Rubio
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
1123 TNFR1 expression on cancer cells is critical for immune escape shaping an immunosuppressive tumor microenvironment
2026
·
Lorena Cañas Zabala
, Elixabet Bolaños
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells
2026
·
Ana Martínez-Riaño
, Raquel Cuesta
, et al.
·
The EMBO Journal
PDF
Figure S5 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Data from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Supplementary Appendix from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
531 A multi-cohort phase 1-2 clinical trial shows safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4–1BB) mAb urelumab in combination with nivolumab
2025
·
Miguel F Sanmamed
, Carlos E De Andrea
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
40
Citation count:
58
H-index:
5
I10-index:
2
Year
Topic
Type